Food and Drug Administration
July 21, 2005
Slides
The Secretary's Advisory Committee on Blood Safety and Availability Update (HTM) (PPT)
Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia and/or Hemoglobinuria Following Rho(D) Immune Globulin Intravenous Administration for Immune Thrombocytopenic Purpura, Ann Gaines, PhD, MT(ASCP), FDA (HTM) (PPT)
Update on the Safety of Albumin, Lawrence Landow, MD, FRCPC, FDA (HTM) (PPT)
Summary: Biological Therapeutics for Rare Plasma Protein Disorders Workshop, Mark Weinstein, PhD, FDA (HTM) (PPT)
Workshop on Leukocyte Reduction of Blood and Blood Components: An Update, Alan Williams, PhD, FDA (HTM) (PPT)
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update, Alan Williams, PhD, FDA (HTM) (PPT)
In Vitro Infectivity of WNV ID NAT Reactive Plasmas that are Positive for Antibodies, Maria Rios, PhD, FDA (HTM) (PPT)
WNV Surveillance Update United States, July 2005, Matthew Kuehnert, MD, FDA (HTM) (PPT)
Management of Donors and Units that Test HBV NAT Postive: Current Considerations, Robin Biswas, MD, FDA (HTM) (PPT)
HBV Seroconversion Panel Results and HBV NAT Positive/Serology Negative Donors, Lary Pietrelli, Roche Molecular Diagnostics (HTM) (PPT)
Temporal Association of HBV NAT and HBsAg Reactivity in Prospectively Screened Source Plasma Donations and Retrospectively Screened Serconversion Panels, Richard Smith, PhD, National Genetics Institute (HTM) (PPT)
Window Period Detection of HBV with the Procleix® Ultrio™ Assay, Larry Mimms, PhD, Gen-Probe Inc. (HTM) (PPT)
Scientific Basis for Review of Varicella Zoster Immune Globulin Products, Dorothy Scott, MD, FDA (HTM) (PPT)
Varicella Zoster Immune Globulin (VZIG), Donna Ambrosino, MD, University of Mass. Medical School (HTM) (PPT)
Varicella-Zoster Virus: Clinical Manifestations & Options for Post-Exposure Prophylaxis, Philip LaRussa, MD, Columbia University (HTM) (PPT)
Recommendations for Postexposoure Prophylaxis of Varicella Infection, Mona Martin, MD, CDC (HTM) (PPT)
Prevention of Dextran-Induced Anaphylactoid Reactions (DIAR) by Hapten Inhibition, Lawrence Landow, MD, FRCPC, FDA (HTM) (PPT)
Prevention of Adverse Reactions to Dextran, Kari-Gösta Ljungström, MD, PhD, Danderyd Hospital, Sweden (HTM) (PPT)
Open Public Hearing
Management of Donors and Units that Test Positive for Hepatitis B Virus (HBV) DNA by Nucleic Acid Tests (NAAT), Roger Dodd, PhD, AABB Transfusion Transmitted Diseases Comm. for AABB, America's Blood Ctrs, American Red Cross (HTM) (PDF) (Word)
Statement by Eileen Bulger, MD, FACS, Co-PI Resuscitation Outcomes Consortium (HTM) (PDF) (Word)
The Risk of Severe DIAR in Trauma Patients Given HSD, Eileen Bulger, MD, Co-PI Resuscitation Outcomes Consortium (HTM) (PPT)